
# SUPERIOR A.R.T. Centre for Assisted Reproduction Technology and Preimplantation Genetic Diagnosis

Low respondence of ovarian stimulation Weena Krutsawad, M.D.

> *Clinical Director, Superior A.R.T., Bangkok, Thailand*



#### "Is there anything new?"


*–Why is this topic so controversial and so current?* 



## Poor Ovarian Response (POR)

- Definition
- Assessment
- Strategies








## Definition : POR

- A systematic review of 47 RCTs revealed 41 different definitions of POR (1)
- To standardize the definition of POR, Ferraretti et al. (2) proposed new criteria, known as the "Bologna criteria," based on three conditions:
  - 1) advanced maternal age (R40 years) or any other POR risk factor;
  - 2) a previous incident of POR; and
  - 3) a low ovarian reserve test in terms of antimullerian hormone (AMH) and antral follicle count (AFC).
  - Two of these three criteria are required for a POR diagnosis.
  - In addition, two cycles with POR after maximal stimulation are sufficient to classify a patient as a poor responder even in the absence of the other criteria mentioned.



SUPERIOR A.R.T.

• New definition of "low prognosis" patients:

1) Introduces two new categories of impaired response:

a. A "suboptimal response," defined as the retrieval of four to nine oocytes, which is associated, at any given age, with a significantly lower live birth rate compared with normal responders i.e., those with 10–15 oocytes (4).

b. A "hyporesponse," in which a higher dose of gonadotropins and more prolonged stimulation are required to obtain an adequate number of oocytes (more than three) (5).

2) Combines "qualitative" and "quantitative" parameters, namely:

a. The age of the patient and the expected aneuploidy rate.

b. Biomarkers and functional markers (i.e., AMH and AFC).

#### Personalize treatment protocols

a. Using different GnRH analogue regimens.

b. Detecting polymorphisms of gonadotropins and their receptors.

c. Tailoring the FSH starting dose.

d. Personalizing gonadotropin doses (i.e., FSH monotherapy or LH-containing drugs).

e. Evaluating special regimens, including oocyte/embryo accumulation to maximize outcomes.





#### Assessment

- Basal FSH
- ✤ AMH
- Inhibin B
- Basal estradiol
- ✤ AFC
- Ovarian volume
- Ovarian vascular flow
- Ovarian biopsy
- Clomiphene citrate challenge test
- Exogenous FSH ovaria reserve test
- GnRH agonist stimulation test
- Multivariate prediction models





Summary of the value of screening tests of ovarian reserve.

		Poor response		Non-pregnancy					
Test	Cutpoint	Sensitivity (%)	Specificity (%)	Sensitivity (%)	Specificity (%)	Reliability	Advantages	Limitations	
FSH	10–20 IU/L	10–80	83–100	7–58	43–100	Limited	Widespread use	Reliability Low sensitivity	
AMH	0.2–0.7 ng/mL	40–97	78–92	a	a	Good	Reliability	Limit of detectability Two commercial assays Does not predict non-pregnancy	
AFC	3–10	9–73	73–100	8–33	64–100	Good	Reliability Widespread use	Low sensitivity	
Inhibin B	40–45 pg/mL	40–80	64–90	а		Limited		Reliability Does not predict non-pregnancy	
CCCT (day-10 FSH)	10–22 IU/L	35–98	68–98	23–61	67–100	Limited	Higher sensitivity than basal FSH	Reliability Limited additional value to basal FSH Requires drug administration	
Note: Laboratories ELISA. <sup>a</sup> Insufficient evidence.									

Practice Committee. Ovarian reserve testing. Fertil Steril 2015.

## Summary of tests of ovarian reserve

#### FSH, AMH, AFC, Inhibit B, CCCT



## Strategies for poor ovarian response

Modifications of ovarian stimulation protocols Other management options



#### Modifications of ovarian stimulation protocols

- Medications
  - Gonadotropin
  - GnRH agonist
  - GnRH antagonist
- Protocol
  - DuoStim
  - Microflare/mini IVF/natural cycle
  - Combination GnRH agonist and antagonist

- Adjuvant therapy
  - Estradiol priming
  - Growth hormone
  - Androgens
  - \* Aspirin
- Alternative treatment
  - Traditional chinese medicine
  - Acupuncture



## Medications


- Gonadotropins
  - Higher starting doses of gonadotropins (450 IU and 600 IU)
  - Long acting gonadotropins (corifollitropin alfa)
  - ✤ uFSH
  - Luteal FSH start/late start/early (D1) start



## Protocol


- Natural cycle with or without minimal stimulation
- FSH/hMG only (no agonist or antagonist)
- DuoStim
- GnRH agonists
  - Combination with GnRH antagonists
  - \* Stop protocol : to lower or to stop the dose of GnRH agonist during luteal phase
  - Decreasing the duration of GnRH agonist use
    - short and ultrashort / mini IVF / micro dose flareup regimens
- GnRH antagonists
  - Initiated during mid-late follicular phase

#### Luteal Estradiol GnRH antagonist Protocol





#### Oral Contraceptive pill/Microdose GnRH agonist Protocol







# Adjuvant therapies

- Estradiol in luteal phase
  - With or without the simultaneous use of GnRH antagonist
- ✤ rLH with rFSH
- Growth hormone (GH) or GHreleasing factor
- Androgens :
  - Oral DHEA before ovarian stimulation
  - Transdermal testosterone

- Low aspirin
- Aromatase Inhibitors (Letrozole)
- Clomiphene Citrate
- Pyridostigmine
- Oral L-arginine
- Dexamethasone
- hCG
- Metformin



Human Reproduction Update, Vol.22, No.3 pp. 306–319, 2016 Advanced Access publication on February 2, 2016 doi:10.1093/humupd/dmw001

human reproduction update

#### Trends in 'poor responder' research: lessons learned from RCTs in assisted conception

#### Athanasios Papathanasiou<sup>1,\*</sup>, Belinda J. Searle, Nicole M.A. King<sup>2</sup>, and Siladitya Bhattacharya<sup>2</sup>

<sup>1</sup>Bourn-Hall Clinic, The Apex, Gateway II, Farrier Close, Wymondham, Norwich NR18 0WF, UK <sup>2</sup>Aberdeen University, Foresterhill, Aberdeen, UK

\*Correspondence address. E-mail: linktothanos@gmail.com

Submitted on September 29, 2015; resubmitted on January 5, 2016; accepted on January 11, 2016

Overall, the majority of published trials on POR suffer from methodological flaws and are, thus, regarded as being high-risk for bias. The same trials have used a variety of definitions for their poor responders and a variety of interventions for their head-to-head comparisons. Not surprisingly, discrepancies are also evident in the findings of trials comparing similar interventions. Based on the identified deficiencies, this novel type of 'methodology and clinical' review has introduced custom recommendations on how to improve future experimental research in the 'poor responder' population.

Table III Interventions with at least one RCT indicating benefit in reproductive outcomes.



SUPERIOR A.R.T. Centre for Assisted Reproductive Technology and Preimplantation Genetic Diagnosis



#### **Table IV** Key clinical facts and trends in 'poor responder' research.

- The most popular criterion for defining 'poor responders' in RCTs has been low ovarian response at previous stimulation
- The most popular cut-off value for defining previous low response is 'less or equal to three retrieved oocytes'
- The most popular tests used in RCTs to define diminished ovarian reserve are AFC and FSH, followed by age and AMH
- Most research interventions were applied before/during controlled ovarian hyperstimulation
- The most popular stimulation protocols investigated in 'poor responder' research are the antagonist protocol, the microdose flare protocol and the long down-regulation protocol
- RCTs on popular protocols for poor responders have reported conflicting results with regard to oocyte yields and reproductive outcomes
- Only I in I0 RCTs has reported statistically significant differences in reproductive outcomes
- No 'positive' intervention is supported by more than one 'positive' RCT



### Conclusions

"The management of patients with impaired or poor ovarian response (POR) remains a controversial and complex clinical issue."